Drug news
First triple combination therapy approved for treatment of multiple myeloma
The National Institute for Health and Care Excellence (NICE) has, after earlier rejections, now recommended Ninlaro (ixazomib) from Takeda together with lenalidomide (Revlimid) and dexamethasone for patients with myeloma after two or three prior treatments. Access for patients will be through the Cancer Drugs Fund. This is the first time that a triple combination has been approved for treatment of the condition in the UK.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.